董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Philip L. Francis | 男 | Director | 67 | 29.00万美元 | 未持股 | 2014-09-08 |
| Edward D. Miller | 男 | Director | 71 | 27.00万美元 | 未持股 | 2014-09-08 |
| Robert P. Wayman | 男 | Director | 69 | 28.00万美元 | 未持股 | 2014-09-08 |
| Robert F. Friel | 男 | Director | 58 | 27.50万美元 | 未持股 | 2014-09-08 |
| Jacqueline B. Kosecoff | 女 | Director | 65 | 27.50万美元 | 未持股 | 2014-09-08 |
| J. Michael Losh | 男 | Director | 67 | 31.50万美元 | 未持股 | 2014-09-08 |
| Michael D. O'halleran | 男 | Director | 64 | 27.50万美元 | 未持股 | 2014-09-08 |
| Kieran T. Gallahue | 男 | Chairman and Chief Executive Officer | 51 | 1078.25万美元 | 未持股 | 2014-09-08 |
| Supratim Bose | 男 | Director | 62 | 10.75万美元 | 未持股 | 2014-09-08 |
| Gregory T. Lucier | 男 | Director | 49 | 29.00万美元 | 未持股 | 2014-09-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan Wygant | 男 | Senior Vice President, Controller and Chief Accounting Officer | 54 | 未披露 | 未持股 | 2014-09-08 |
| Jonathan Wygant | 男 | Senior Vice President, Controller and Chief Accounting Officer | 54 | 未披露 | 未持股 | 2014-09-08 |
| Kieran T. Gallahue | 男 | Chairman and Chief Executive Officer | 51 | 1078.25万美元 | 未持股 | 2014-09-08 |
| James F. Hinrichs | 男 | Chief Financial Officer | 58 | 361.27万美元 | 未持股 | 2014-09-08 |
| Thomas J. Leonard | 男 | President, Medical Systems | 57 | 255.57万美元 | 未持股 | 2014-09-08 |
| Joan Stafslien | 女 | Executive Vice President, General Counsel and Corporate Secretary | 60 | 215.40万美元 | 未持股 | 2014-09-08 |
| Gordon LaFortune | 男 | Executive Vice President, EMEA/ANZ Commercial Operations and Global Infusion Disposables | 67 | 195.11万美元 | 未持股 | 2014-09-08 |
| Donald Abbey | 男 | Executive Vice President, Quality, Regulatory and Medical Affairs | 58 | 未披露 | 未持股 | 2014-09-08 |
董事简历
中英对照 | 中文 | 英文- Philip L. Francis
-
Philip L. Francis从2009年6月直到2012年1月退休，担任PetSmart公司（一家专业的宠物零售商）的执行董事长。自1999年到他获委任为执行董事长期间，他曾任PetSmart董事长兼首席执行官。过往五年中，他是SUPERVALU公司的首席董事。他还担任PetSmart公司和Cardinal Health的董事会成员。
Philip L. Francis most recently served as Chairman of PetSmart, Inc. from 2009 to 2012 and as Chairman and Chief Executive Officer from 2001 to 2009. Mr. Francis served on the boards of Supervalu, Inc. from 2006 to 2018 PetSmart, Inc. from 1989 to 2013 Cardinal Health, Inc. from 2006 to 2009 and CareFusion Inc. from 2009 to 2015. Mr. Francis received his M.B.A. from Indiana University in Marketing and Management and his Bachelor of Science in Agricultural Science from University of Illinois at Urbana-Champaign. - Philip L. Francis从2009年6月直到2012年1月退休，担任PetSmart公司（一家专业的宠物零售商）的执行董事长。自1999年到他获委任为执行董事长期间，他曾任PetSmart董事长兼首席执行官。过往五年中，他是SUPERVALU公司的首席董事。他还担任PetSmart公司和Cardinal Health的董事会成员。
- Philip L. Francis most recently served as Chairman of PetSmart, Inc. from 2009 to 2012 and as Chairman and Chief Executive Officer from 2001 to 2009. Mr. Francis served on the boards of Supervalu, Inc. from 2006 to 2018 PetSmart, Inc. from 1989 to 2013 Cardinal Health, Inc. from 2006 to 2009 and CareFusion Inc. from 2009 to 2015. Mr. Francis received his M.B.A. from Indiana University in Marketing and Management and his Bachelor of Science in Agricultural Science from University of Illinois at Urbana-Champaign.
- Edward D. Miller
-
Edward D. Miller是美国约翰霍普金斯大学医学院麻醉和重症监护医学方面的教授。此前，他曾担任美国约翰霍普金斯医学院，其中包括约翰霍普金斯大学医学院和约翰霍普金斯大学卫生系统和医院的首席执行官；从1997年1月直到2012年6月退休，担任美国约翰霍普金斯大学医学院医疗学院院长。他于1994年作为一名麻醉学教授和重症护理医学部主任，加入约翰霍普金斯大学。在加入约翰霍普金斯大学之前，他曾在不同的医院及学术机构担任教授、研究员、临床工作者等职务。过往五年中，他是PNC互惠基金公司的董事，他还担任了PNC另类策略基金有限责任公司的董事。
Edward D. Miller has been a director of the Company since 2009. Dr. Miller is currently a professor of anesthesiology and critical care medicine at The Johns Hopkins University School of Medicine. He previously served as chief executive officer of Johns Hopkins Medicine, which encompasses The Johns Hopkins University School of Medicine and The Johns Hopkins Health System and Hospital, and as dean of the medical faculty of The Johns Hopkins University School of Medicine from January 1997 until his retirement in June 2012. Dr. Miller joined Johns Hopkins in 1994 as a professor and director of the department of anesthesiology and critical care medicine. Prior to joining Johns Hopkins, Dr. Miller held positions as a professor, researcher and clinician at various hospitals and academic institutions. He is a director of PNC Mutual Funds, Inc. During the prior five years, he also served on the board of PNC Alternative Strategies Fund LLC. - Edward D. Miller是美国约翰霍普金斯大学医学院麻醉和重症监护医学方面的教授。此前，他曾担任美国约翰霍普金斯医学院，其中包括约翰霍普金斯大学医学院和约翰霍普金斯大学卫生系统和医院的首席执行官；从1997年1月直到2012年6月退休，担任美国约翰霍普金斯大学医学院医疗学院院长。他于1994年作为一名麻醉学教授和重症护理医学部主任，加入约翰霍普金斯大学。在加入约翰霍普金斯大学之前，他曾在不同的医院及学术机构担任教授、研究员、临床工作者等职务。过往五年中，他是PNC互惠基金公司的董事，他还担任了PNC另类策略基金有限责任公司的董事。
- Edward D. Miller has been a director of the Company since 2009. Dr. Miller is currently a professor of anesthesiology and critical care medicine at The Johns Hopkins University School of Medicine. He previously served as chief executive officer of Johns Hopkins Medicine, which encompasses The Johns Hopkins University School of Medicine and The Johns Hopkins Health System and Hospital, and as dean of the medical faculty of The Johns Hopkins University School of Medicine from January 1997 until his retirement in June 2012. Dr. Miller joined Johns Hopkins in 1994 as a professor and director of the department of anesthesiology and critical care medicine. Prior to joining Johns Hopkins, Dr. Miller held positions as a professor, researcher and clinician at various hospitals and academic institutions. He is a director of PNC Mutual Funds, Inc. During the prior five years, he also served on the board of PNC Alternative Strategies Fund LLC.
- Robert P. Wayman
-
Robert P. Wayman自2008年9月起一直担任董事。2007年1月，他以惠普公司（一家跨国信息技术公司）财务总监的身份退休。他自1984年起就担任此职位。自1992年起就担任负责财务和行政执行副总裁。他在惠普36年的职业生涯中，他还自2005年2月至2005年3月担任过惠普临时首席执行官，1993年至2002年和2005年2月至2007年3月担任惠普董事会成员。他目前是Affymetrix公司和CareFusion公司的董事，并曾担任Sybase公司的董事。他在获得西北大学工程学士学位和MBA学位。他带给董事会广泛的业务和行政领导经验，包括担任财务总监。
Robert P. Wayman has been a director since September 2008. In January 2007 Mr. Wayman retired from his position as Chief Financial Officer of Hewlett-Packard Company, a multinational information technology company, a position he held since 1984 and as HP's Executive Vice President, Finance and Administration, a position he held since 1992. During his 36-year career with HP, Mr. Wayman also served as HP's interim Chief Executive Officer from February 2005 until March 2005 and as a member of HP's board of directors from 1993 to 2002 and from February 2005 until March 2007. Mr. Wayman previously served as a director of Sybase Inc. and CareFusion Corporation. Mr. Wayman received a B.S. in engineering and an M.B.A. from Northwestern University. - Robert P. Wayman自2008年9月起一直担任董事。2007年1月，他以惠普公司（一家跨国信息技术公司）财务总监的身份退休。他自1984年起就担任此职位。自1992年起就担任负责财务和行政执行副总裁。他在惠普36年的职业生涯中，他还自2005年2月至2005年3月担任过惠普临时首席执行官，1993年至2002年和2005年2月至2007年3月担任惠普董事会成员。他目前是Affymetrix公司和CareFusion公司的董事，并曾担任Sybase公司的董事。他在获得西北大学工程学士学位和MBA学位。他带给董事会广泛的业务和行政领导经验，包括担任财务总监。
- Robert P. Wayman has been a director since September 2008. In January 2007 Mr. Wayman retired from his position as Chief Financial Officer of Hewlett-Packard Company, a multinational information technology company, a position he held since 1984 and as HP's Executive Vice President, Finance and Administration, a position he held since 1992. During his 36-year career with HP, Mr. Wayman also served as HP's interim Chief Executive Officer from February 2005 until March 2005 and as a member of HP's board of directors from 1993 to 2002 and from February 2005 until March 2007. Mr. Wayman previously served as a director of Sybase Inc. and CareFusion Corporation. Mr. Wayman received a B.S. in engineering and an M.B.A. from Northwestern University.
- Robert F. Friel
-
Robert F. Friel目前担任Perkin Elmer公司的主席、行政总裁兼总裁。在2008年2月被任命为总裁兼首席执行官和2009年4月被任命为董事长之前，他自2007年8月起担任总裁兼首席运营官，自2006年1月起担任副董事长兼总裁，从2004年10月至2006年1月除了监督财务外还负责业务发展和信息技术。1999年2月，他作为公司执行副总裁兼财务总监加入Perkin Elmer。在加入公司之前，他在AlliedSignal公司（现在是Honeywell International）担任多个高级管理职位。他从费尔利迪金森大学获得经济学学士学位，从拉斐特学院获得税务学硕士学位。他目前是CareFusion公司和Xylem公司的董事，并曾担任Fairchild半导体公司和千年制药公司的董事。他还曾担任国家局优生优育基金会的信托董事。主要职位：Perkin Elmer的主席、行政总裁兼总裁、2006年起Perkin Elmer的董事以及财务委员会委员。
Robert F. Friel,Perkin Elmer (1999-2019), serving as Chief Operating Officer, Chief Financial Officer and in other senior leadership roles;Mr. Friel holds a Master of Science degree in taxation from Fairleigh Dickinson University and a Bachelor of Arts degree in economics from Lafayette College. In addition to the public board membership listed above, Mr. Friel is a director of New York Life Insurance Company, one of the largest life insurers in the world. - Robert F. Friel目前担任Perkin Elmer公司的主席、行政总裁兼总裁。在2008年2月被任命为总裁兼首席执行官和2009年4月被任命为董事长之前，他自2007年8月起担任总裁兼首席运营官，自2006年1月起担任副董事长兼总裁，从2004年10月至2006年1月除了监督财务外还负责业务发展和信息技术。1999年2月，他作为公司执行副总裁兼财务总监加入Perkin Elmer。在加入公司之前，他在AlliedSignal公司（现在是Honeywell International）担任多个高级管理职位。他从费尔利迪金森大学获得经济学学士学位，从拉斐特学院获得税务学硕士学位。他目前是CareFusion公司和Xylem公司的董事，并曾担任Fairchild半导体公司和千年制药公司的董事。他还曾担任国家局优生优育基金会的信托董事。主要职位：Perkin Elmer的主席、行政总裁兼总裁、2006年起Perkin Elmer的董事以及财务委员会委员。
- Robert F. Friel,Perkin Elmer (1999-2019), serving as Chief Operating Officer, Chief Financial Officer and in other senior leadership roles;Mr. Friel holds a Master of Science degree in taxation from Fairleigh Dickinson University and a Bachelor of Arts degree in economics from Lafayette College. In addition to the public board membership listed above, Mr. Friel is a director of New York Life Insurance Company, one of the largest life insurers in the world.
- Jacqueline B. Kosecoff
-
Jacqueline B. Kosecoff自2012年3月起担任Moriah Partners, LLC（一家专注于医疗服务和技术的私募股权公司）的管理伙伴；担任美国华平投资集团有限责任公司（一家全球性私人股权投资公司）的高级顾问。从2007年10月至2011年11月，她曾担任OptumRx原处方解决方案公司（药房福利管理公司和UnitedHealth集团之附属公司）的行政总裁，并从2011年12月至2012年2月继续担任OptumRx的高级顾问。从2005年12月至2007年10月，她曾担任Ovations解决方案公司 （UnitedHealth集团的附属公司，为年龄50+的人提供健康和福祉服务）的首席执行官。从2002年7月至2005年12月，她担任Specialty Companies of PacifiCare Health Systems, Inc.（一个消费者健康组织）的执行副总裁。她是Sealed Air Corporation, Steris Corporation和athenahealth, Inc.的董事。
Jacqueline B. Kosecoff,is a Managing Partner of Moriah Partners, where since March 2012, she has worked to identify, select, mentor and manage health services and IT companies. Dr. Kosecoff also has been a Senior Advisor at Warburg Pincus since March 2012. From 2002 to 2012, Dr. Kosecoff was a senior executive inside UnitedHealth Group-PacifiCare. Dr. Kosecoff joined UnitedHealth Group as part of its acquisition of PacifiCare Health Systems in 2005. At PacifiCare, Dr. Kosecoff served as Executive Vice President with responsibility for various business segments and, upon joining UnitedHealth Group, Dr. Kosecoff was appointed Chief Executive Officer of OptumRx (previously known as Prescription Solutions). Prior to joining UnitedHealth Group-PacifiCare, Dr. Kosecoff was founder and President of Protocare, a firm whose lines of business included the clinical development of drugs, devices, biopharmaceutical and nutritional products, and health services consulting. Dr. Kosecoff was also co-Founder and co-CEO of Value Health Sciences. Dr. Kosecoff served as Professor of Medicine and Public Health at the University of California, Los Angeles from 1975 to 2006. From July 2012 through February 2019, Dr. Kosecoff served on the board of directors of athenahealth, Inc. From May 2005 to May 2021, she served on the board of directors of Sealed Air Corporation. From September 2020 to June 2023 she also served on the board of directors of GoodRx, Inc. Currently, Dr. Kosecoff sits on the board of directors of these public companies; Alignment Healthcare, and TriNet Group, Inc. Dr. Kosecoff holds a B.A. from the University of California, Los Angeles, an M.S. in Applied Mathematics from Brown University, and a doctorate from University of California, Los Angeles. - Jacqueline B. Kosecoff自2012年3月起担任Moriah Partners, LLC（一家专注于医疗服务和技术的私募股权公司）的管理伙伴；担任美国华平投资集团有限责任公司（一家全球性私人股权投资公司）的高级顾问。从2007年10月至2011年11月，她曾担任OptumRx原处方解决方案公司（药房福利管理公司和UnitedHealth集团之附属公司）的行政总裁，并从2011年12月至2012年2月继续担任OptumRx的高级顾问。从2005年12月至2007年10月，她曾担任Ovations解决方案公司 （UnitedHealth集团的附属公司，为年龄50+的人提供健康和福祉服务）的首席执行官。从2002年7月至2005年12月，她担任Specialty Companies of PacifiCare Health Systems, Inc.（一个消费者健康组织）的执行副总裁。她是Sealed Air Corporation, Steris Corporation和athenahealth, Inc.的董事。
- Jacqueline B. Kosecoff,is a Managing Partner of Moriah Partners, where since March 2012, she has worked to identify, select, mentor and manage health services and IT companies. Dr. Kosecoff also has been a Senior Advisor at Warburg Pincus since March 2012. From 2002 to 2012, Dr. Kosecoff was a senior executive inside UnitedHealth Group-PacifiCare. Dr. Kosecoff joined UnitedHealth Group as part of its acquisition of PacifiCare Health Systems in 2005. At PacifiCare, Dr. Kosecoff served as Executive Vice President with responsibility for various business segments and, upon joining UnitedHealth Group, Dr. Kosecoff was appointed Chief Executive Officer of OptumRx (previously known as Prescription Solutions). Prior to joining UnitedHealth Group-PacifiCare, Dr. Kosecoff was founder and President of Protocare, a firm whose lines of business included the clinical development of drugs, devices, biopharmaceutical and nutritional products, and health services consulting. Dr. Kosecoff was also co-Founder and co-CEO of Value Health Sciences. Dr. Kosecoff served as Professor of Medicine and Public Health at the University of California, Los Angeles from 1975 to 2006. From July 2012 through February 2019, Dr. Kosecoff served on the board of directors of athenahealth, Inc. From May 2005 to May 2021, she served on the board of directors of Sealed Air Corporation. From September 2020 to June 2023 she also served on the board of directors of GoodRx, Inc. Currently, Dr. Kosecoff sits on the board of directors of these public companies; Alignment Healthcare, and TriNet Group, Inc. Dr. Kosecoff holds a B.A. from the University of California, Los Angeles, an M.S. in Applied Mathematics from Brown University, and a doctorate from University of California, Los Angeles.
- J. Michael Losh
-
J. Michael Losh，自2018年2月起担任Amesite Inc.董事会成员。2004年7月至2005年5月，他担任Cardinal Health的首席财务官。1964年至2000年，他在通用汽车公司工作。1994年7月至2000年8月，他担任通用汽车公司的首席财务官和执行副总裁。他是Aon PLC（纽约证券交易所代码：Aon）的董事（2003年至今）和Cardinal Health Inc.（纽约证券交易所代码：CAH）的董事（1996年至2009年和2018年至2021年）。他曾担任AMB Corp.、Care Fusion Inc.、Electronic Data Systems Corp.、Delphi Automotive Systems Corp.、Hughes Electronics、Quaker Oats Company、TRW Automotive Inc.、HB Fuller Co 。和Prologis， Inc.的董事。他曾担任GMAC， Metaldyne Corp.和Masco Corp. （NYSE： MAS）的董事会主席。他持有Kettering大学的机械工程学士学位和Harvard大学的工商管理硕士学位。
J. Michael Losh has served as a member of board of directors since February 2018. Mr. Losh served as the Chief Financial Officer at Cardinal Health from July 2004 to May 2005. Mr. Losh was with General Motors from 1964 to 2000. He served as the Chief Financial Officer and Executive Vice President of General Motors Corp., from July 1994 to Augt 2000. He is a Director at Aon PLC (NYSE: AON) (2003 present) and a Director at Cardinal Health Inc. (NYSE: CAH) (1996 to 2009 and 2018 to 2021). Mr. Losh has served as a director of AMB Corp., Care Fion Inc., Electronic Data Systems Corp., Delphi Automotive Systems Corp., Hughes Electronics, Quaker Oats Company, TRW Automotive Inc., HB Fuller Co, and Prologis, Inc. He served as Chairman of the boards of GMAC, Metaldyne Corp, and Masco Corp. (NYSE: MAS). Mr. Losh holds a B.S. in Mechanical Engineering from Kettering University and an M.B.A. from Harvard University. - J. Michael Losh，自2018年2月起担任Amesite Inc.董事会成员。2004年7月至2005年5月，他担任Cardinal Health的首席财务官。1964年至2000年，他在通用汽车公司工作。1994年7月至2000年8月，他担任通用汽车公司的首席财务官和执行副总裁。他是Aon PLC（纽约证券交易所代码：Aon）的董事（2003年至今）和Cardinal Health Inc.（纽约证券交易所代码：CAH）的董事（1996年至2009年和2018年至2021年）。他曾担任AMB Corp.、Care Fusion Inc.、Electronic Data Systems Corp.、Delphi Automotive Systems Corp.、Hughes Electronics、Quaker Oats Company、TRW Automotive Inc.、HB Fuller Co 。和Prologis， Inc.的董事。他曾担任GMAC， Metaldyne Corp.和Masco Corp. （NYSE： MAS）的董事会主席。他持有Kettering大学的机械工程学士学位和Harvard大学的工商管理硕士学位。
- J. Michael Losh has served as a member of board of directors since February 2018. Mr. Losh served as the Chief Financial Officer at Cardinal Health from July 2004 to May 2005. Mr. Losh was with General Motors from 1964 to 2000. He served as the Chief Financial Officer and Executive Vice President of General Motors Corp., from July 1994 to Augt 2000. He is a Director at Aon PLC (NYSE: AON) (2003 present) and a Director at Cardinal Health Inc. (NYSE: CAH) (1996 to 2009 and 2018 to 2021). Mr. Losh has served as a director of AMB Corp., Care Fion Inc., Electronic Data Systems Corp., Delphi Automotive Systems Corp., Hughes Electronics, Quaker Oats Company, TRW Automotive Inc., HB Fuller Co, and Prologis, Inc. He served as Chairman of the boards of GMAC, Metaldyne Corp, and Masco Corp. (NYSE: MAS). Mr. Losh holds a B.S. in Mechanical Engineering from Kettering University and an M.B.A. from Harvard University.
- Michael D. O'halleran
-
Michael D. O'halleran自2004年9月起出任Aon PLC（一家风险管理、保险和咨询服务提供商）的高级执行副总裁。从1999年至2004年， 他担任Aon公司的总裁兼首席营运官。1987年，他加入Aon，领导再保险部门。自那时起，他曾在Aon集团旗下多个公司担任重要的管理职位，包括自2007年8月Aon Benfield的执行主席，Aon公司提供再保险及经纪服务的部门。在过往五年中，他曾担任Cardinal Health的董事会成员。
Michael D. O'halleran, Mr. O'Halleran has served as senior executive vice president of Aon PLC, a provider of risk management, insurance and consulting services, since September 2004. From 1999 to 2004 Mr. O'Halleran served as president and chief operating officer of Aon Corporation. Mr. O'Halleran joined Aon in 1987 to lead its reinsurance division. Since that time, he has served in several significant management positions within the Aon group of companies including, since August 2007 as the executive chairman of Aon Benfield, the division of Aon Corporation that provides reinsurance and brokerage services. During the prior five years, Mr. O'Halleran served on the board of Cardinal Health. - Michael D. O'halleran自2004年9月起出任Aon PLC（一家风险管理、保险和咨询服务提供商）的高级执行副总裁。从1999年至2004年， 他担任Aon公司的总裁兼首席营运官。1987年，他加入Aon，领导再保险部门。自那时起，他曾在Aon集团旗下多个公司担任重要的管理职位，包括自2007年8月Aon Benfield的执行主席，Aon公司提供再保险及经纪服务的部门。在过往五年中，他曾担任Cardinal Health的董事会成员。
- Michael D. O'halleran, Mr. O'Halleran has served as senior executive vice president of Aon PLC, a provider of risk management, insurance and consulting services, since September 2004. From 1999 to 2004 Mr. O'Halleran served as president and chief operating officer of Aon Corporation. Mr. O'Halleran joined Aon in 1987 to lead its reinsurance division. Since that time, he has served in several significant management positions within the Aon group of companies including, since August 2007 as the executive chairman of Aon Benfield, the division of Aon Corporation that provides reinsurance and brokerage services. During the prior five years, Mr. O'Halleran served on the board of Cardinal Health.
- Kieran T. Gallahue
-
Kieran T. Gallahue是公司董事会主席及行政总裁。在2011年1月加入公司之前，他担任瑞思迈公司（一家服务于睡眠呼吸障碍和呼吸市场的医疗器械公司）的董事、总裁兼首席执行官。 他于2003年1月加入瑞思迈，成为美洲公司的总裁兼首席运营官，并于2004年9月晋升至瑞思迈公司的总裁。在2008年1月被任命为公司总裁、首席执行官兼董事之前，他曾担任多个职务。在加入瑞思迈之前，从1998年1月至2002年12月，他在Nanogen公司（一家DNA研究和医疗诊断公司）担任多个职务，包括总裁兼首席财务官。在1998年之前他在仪器实验室、宝洁公司和通用电气公司担任各类营销、销售和财务职位。他是Volcano公司的董事。在过往五年中， 他还担任瑞思迈的董事。
Kieran T. Gallahue,Other Current Public Company Directorships:Envista Holdings Corporation, since 2019;Chair of the Nominating and Governance Committee, since 2019.Other Public Company Directorships Previously Held:Arena Pharmaceuticals, Inc., from 2018 to 2022;Member of the Audit Committee, from 2018 to 2022;Intersect ENT, Inc., from 2015 to 2022;Chairman of the Board, from 2020 to 2022;Member of the Audit Committee, from 2015 to 2022;CareFusion Corporation, from 2011 to 2015;Volcano Corporation, from 2007 to 2015;ResMed, Inc., from 2008 to 2011.Select Professional Experience and Highlights:CareFusion Corporation, a global medical technology company (acquired by Becton, Dickinson and Company in March 2015);Chairman and Chief Executive Officer, from 2011 until his retirement in 2015;ResMed, Inc. Chief Executive Officer, from 2008 to 2011;President, from 2004 to 2011;President and Chief Operating Officer, Americas, from 2003 to 2004.Nanogen, Inc. Various positions, including President and Chief Financial Officer, from 1998 to 2002;Prior to 1998, various marketing, sales, and financial positions within Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company.Served on the Board and Executive Committee, and as Chairman of the International Committee and Treasurer of Advanced Medical Technology Association (AdvaMed). - Kieran T. Gallahue是公司董事会主席及行政总裁。在2011年1月加入公司之前，他担任瑞思迈公司（一家服务于睡眠呼吸障碍和呼吸市场的医疗器械公司）的董事、总裁兼首席执行官。 他于2003年1月加入瑞思迈，成为美洲公司的总裁兼首席运营官，并于2004年9月晋升至瑞思迈公司的总裁。在2008年1月被任命为公司总裁、首席执行官兼董事之前，他曾担任多个职务。在加入瑞思迈之前，从1998年1月至2002年12月，他在Nanogen公司（一家DNA研究和医疗诊断公司）担任多个职务，包括总裁兼首席财务官。在1998年之前他在仪器实验室、宝洁公司和通用电气公司担任各类营销、销售和财务职位。他是Volcano公司的董事。在过往五年中， 他还担任瑞思迈的董事。
- Kieran T. Gallahue,Other Current Public Company Directorships:Envista Holdings Corporation, since 2019;Chair of the Nominating and Governance Committee, since 2019.Other Public Company Directorships Previously Held:Arena Pharmaceuticals, Inc., from 2018 to 2022;Member of the Audit Committee, from 2018 to 2022;Intersect ENT, Inc., from 2015 to 2022;Chairman of the Board, from 2020 to 2022;Member of the Audit Committee, from 2015 to 2022;CareFusion Corporation, from 2011 to 2015;Volcano Corporation, from 2007 to 2015;ResMed, Inc., from 2008 to 2011.Select Professional Experience and Highlights:CareFusion Corporation, a global medical technology company (acquired by Becton, Dickinson and Company in March 2015);Chairman and Chief Executive Officer, from 2011 until his retirement in 2015;ResMed, Inc. Chief Executive Officer, from 2008 to 2011;President, from 2004 to 2011;President and Chief Operating Officer, Americas, from 2003 to 2004.Nanogen, Inc. Various positions, including President and Chief Financial Officer, from 1998 to 2002;Prior to 1998, various marketing, sales, and financial positions within Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company.Served on the Board and Executive Committee, and as Chairman of the International Committee and Treasurer of Advanced Medical Technology Association (AdvaMed).
- Supratim Bose
-
Supratim Bose，本公司亚太区、中东区及非洲区执行副总裁兼总裁，并自2013年1月起担任该职务。他于2011年12月加入波士顿科学公司，担任本公司亚太执行副总裁兼总裁；直到他也担任本公司的中东和非洲国际区的事务。在加入该公司前， 从2010年1月到2011年12月，博思先生是Bose咨询集团驻新加坡创始人和首席执行官， 该公司致力于为医疗行业进行战略管理咨询服务。此前，他曾在强生公司工作了近三十年，并在2009年结束了他作为该公司医疗设备和诊断业务集团董事长的职务。他于1981年加入强生印度有限公司，举办了担任各种具有越来越多责任的管理职位。他持有孟买大学Jamnalal巴贾吉管理学院化学物理学士学位、生物物理学硕士学位。他曾担任Quattro Vascular Pte有限公司和Trireme医疗公司董事会任职，并担任新加坡管理大学李光前商学院顾问委员会的成员。
Supratim Bose is our Executive Vice President and President, Asia-Pacific, Middle East and Africa, a position he has held since January 2013. Mr. Bose joined Boston Scientific in December 2011 as our Executive Vice President and President, Asia-Pacific and served in that role until he also assumed responsibility for the Middle East and Africa units. Before joining Boston Scientific, Mr. Bose was founder and Chief Executive Officer of Singapore-based Bose Consulting Group, which specialized in strategic management consulting services for the healthcare industry, from January 2010 to December 2011. He previously worked for nearly thirty years at Johnson & Johnson where he concluded his tenure as Company Group Chairman of its Medical Devices and Diagnostics business in 2009. Mr. Bose joined Johnson & Johnson Ltd. India in 1981 and held a variety of management positions of increasing responsibility. He earned a B.S. in Chemistry/Physics, an M.S. in Biophysics and a Masters in Management Studies from the Jamnalal Bajaj Institute for Management Studies at the University of Bombay. He has served as a member of the board of directors at Quattro Vascular Pte. Ltd. and Trireme Medical, and as a member of the advisory board at Singapore Management University's Lee Kong Chian School of Business. He served as a member of the board of directors of CareFusion Corporation, a role that he held from May 2014 until that company's acquisition by Becton, Dickinson and Company in March 2015. - Supratim Bose，本公司亚太区、中东区及非洲区执行副总裁兼总裁，并自2013年1月起担任该职务。他于2011年12月加入波士顿科学公司，担任本公司亚太执行副总裁兼总裁；直到他也担任本公司的中东和非洲国际区的事务。在加入该公司前， 从2010年1月到2011年12月，博思先生是Bose咨询集团驻新加坡创始人和首席执行官， 该公司致力于为医疗行业进行战略管理咨询服务。此前，他曾在强生公司工作了近三十年，并在2009年结束了他作为该公司医疗设备和诊断业务集团董事长的职务。他于1981年加入强生印度有限公司，举办了担任各种具有越来越多责任的管理职位。他持有孟买大学Jamnalal巴贾吉管理学院化学物理学士学位、生物物理学硕士学位。他曾担任Quattro Vascular Pte有限公司和Trireme医疗公司董事会任职，并担任新加坡管理大学李光前商学院顾问委员会的成员。
- Supratim Bose is our Executive Vice President and President, Asia-Pacific, Middle East and Africa, a position he has held since January 2013. Mr. Bose joined Boston Scientific in December 2011 as our Executive Vice President and President, Asia-Pacific and served in that role until he also assumed responsibility for the Middle East and Africa units. Before joining Boston Scientific, Mr. Bose was founder and Chief Executive Officer of Singapore-based Bose Consulting Group, which specialized in strategic management consulting services for the healthcare industry, from January 2010 to December 2011. He previously worked for nearly thirty years at Johnson & Johnson where he concluded his tenure as Company Group Chairman of its Medical Devices and Diagnostics business in 2009. Mr. Bose joined Johnson & Johnson Ltd. India in 1981 and held a variety of management positions of increasing responsibility. He earned a B.S. in Chemistry/Physics, an M.S. in Biophysics and a Masters in Management Studies from the Jamnalal Bajaj Institute for Management Studies at the University of Bombay. He has served as a member of the board of directors at Quattro Vascular Pte. Ltd. and Trireme Medical, and as a member of the advisory board at Singapore Management University's Lee Kong Chian School of Business. He served as a member of the board of directors of CareFusion Corporation, a role that he held from May 2014 until that company's acquisition by Becton, Dickinson and Company in March 2015.
- Gregory T. Lucier
-
Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier is the chief executive officer of Corza Health, Inc. a company focused on acquiring healthcare companies and assets since April 2019. Prior to that, he served as Chairman and Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of Dentsply Sirona and a director at Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University. - Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
- Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier is the chief executive officer of Corza Health, Inc. a company focused on acquiring healthcare companies and assets since April 2019. Prior to that, he served as Chairman and Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of Dentsply Sirona and a director at Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Jonathan Wygant
Jonathan Wygant,2013年8月以来,他一直担任我们的高级副总裁、总会计师兼首席会计官。从2010年5月到2013年8月，他曾担任我们的财务副总裁，以及助理总会计师。从2009年8月到2010年5月，他曾担任财务董事。我们公司于2009年8月从Cardinal Health公司剥离出来。此前，他曾担任 Cardinal Health公司的财务董事，负责临床和医疗产品。他于2004年7月加入Cardinal Health公司，担任财务经理，随后Cardinal Health公司收购Alaris公司。她于2003年4月加入Alaris公司，担任高级财务分析师，并2004年5月被提升为财务经理。加入Alaris公司之前，他曾担任普华永道（PricewaterhouseCoopers）的会计公司的高级审计师。
Jonathan Wygant,Mr. Wygant has been our Senior Vice President, Controller and Chief Accounting Officer since August 2013. From May 2010 to August 2013 Mr. Wygant was our Vice President, Finance and Assistant Controller. From August 2009 to May 2010 Mr. Wygant served as a Director, Finance. Prior to our spinoff from Cardinal Health in August 2009 he served as Director, Finance - Clinical and Medical Products of Cardinal Health. Mr. Wygant joined Cardinal Health in July 2004 as a Finance Manager, following Cardinal Health’s acquisition of Alaris. Mr. Wygant joined Alaris in April 2003 as a Senior Financial Analyst and was promoted to Finance Manager in May 2004. Prior to joining Alaris, he was a senior auditor with the accounting firm of PricewaterhouseCoopers LLP.- Jonathan Wygant,2013年8月以来,他一直担任我们的高级副总裁、总会计师兼首席会计官。从2010年5月到2013年8月，他曾担任我们的财务副总裁，以及助理总会计师。从2009年8月到2010年5月，他曾担任财务董事。我们公司于2009年8月从Cardinal Health公司剥离出来。此前，他曾担任 Cardinal Health公司的财务董事，负责临床和医疗产品。他于2004年7月加入Cardinal Health公司，担任财务经理，随后Cardinal Health公司收购Alaris公司。她于2003年4月加入Alaris公司，担任高级财务分析师，并2004年5月被提升为财务经理。加入Alaris公司之前，他曾担任普华永道（PricewaterhouseCoopers）的会计公司的高级审计师。
- Jonathan Wygant,Mr. Wygant has been our Senior Vice President, Controller and Chief Accounting Officer since August 2013. From May 2010 to August 2013 Mr. Wygant was our Vice President, Finance and Assistant Controller. From August 2009 to May 2010 Mr. Wygant served as a Director, Finance. Prior to our spinoff from Cardinal Health in August 2009 he served as Director, Finance - Clinical and Medical Products of Cardinal Health. Mr. Wygant joined Cardinal Health in July 2004 as a Finance Manager, following Cardinal Health’s acquisition of Alaris. Mr. Wygant joined Alaris in April 2003 as a Senior Financial Analyst and was promoted to Finance Manager in May 2004. Prior to joining Alaris, he was a senior auditor with the accounting firm of PricewaterhouseCoopers LLP.
- Jonathan Wygant
Jonathan Wygant，他曾一直担任我们的首席会计官和总会计师（2016年4月以来），以及我们的财务副总裁（2016年1月以来）。2013年8月至加入我们，他曾担任CareFusion Corporation的高级副总裁、总会计师和首席会计官。2010年5月至2013年8月，他曾担任CareFusion公司的财务副总裁兼助理总会计师。2009年8月至2010年5月，他曾担任CareFusion公司的财务董事。2009年8月CareFusion公司从Cardinal Health拆分出来之前，他曾担任Cardinal Health公司的财务董事，负责临床和医疗产品。他此前曾担任多种其它会计职务，包括PricewaterhouseCoopers LLP的会计师事务所的高级审计师。
Jonathan Wygant serves as Cibus Ltd.’s Chief Accounting Officer and has served as Vice President & Corporate Controller of Cibus Global since May 2018. Mr. Wygant was previously the Corporate Controller and Chief Accounting Officer of Alere, Inc., a diagnostic company, from January 2016 until its sale to Abbott in October of 2017 for approximately $8 billion. Prior to Alere, he served as Corporate Controller and Chief Accounting Officer of CareFusion Corp., a global medical device company, from August 2013 until its sale to Becton Dickinson for $12 billion in March of 2015. His prior experience includes senior finance roles at CareFusion, Cardinal Health and Alaris Medical Systems, a global medical device company purchased by Cardinal Health for $4 billion in 2004 as well as a senior auditor position with PricewaterhouseCoopers. He holds an undergraduate degree in accounting from the University of San Diego.- Jonathan Wygant，他曾一直担任我们的首席会计官和总会计师（2016年4月以来），以及我们的财务副总裁（2016年1月以来）。2013年8月至加入我们，他曾担任CareFusion Corporation的高级副总裁、总会计师和首席会计官。2010年5月至2013年8月，他曾担任CareFusion公司的财务副总裁兼助理总会计师。2009年8月至2010年5月，他曾担任CareFusion公司的财务董事。2009年8月CareFusion公司从Cardinal Health拆分出来之前，他曾担任Cardinal Health公司的财务董事，负责临床和医疗产品。他此前曾担任多种其它会计职务，包括PricewaterhouseCoopers LLP的会计师事务所的高级审计师。
- Jonathan Wygant serves as Cibus Ltd.’s Chief Accounting Officer and has served as Vice President & Corporate Controller of Cibus Global since May 2018. Mr. Wygant was previously the Corporate Controller and Chief Accounting Officer of Alere, Inc., a diagnostic company, from January 2016 until its sale to Abbott in October of 2017 for approximately $8 billion. Prior to Alere, he served as Corporate Controller and Chief Accounting Officer of CareFusion Corp., a global medical device company, from August 2013 until its sale to Becton Dickinson for $12 billion in March of 2015. His prior experience includes senior finance roles at CareFusion, Cardinal Health and Alaris Medical Systems, a global medical device company purchased by Cardinal Health for $4 billion in 2004 as well as a senior auditor position with PricewaterhouseCoopers. He holds an undergraduate degree in accounting from the University of San Diego.
- Kieran T. Gallahue
Kieran T. Gallahue是公司董事会主席及行政总裁。在2011年1月加入公司之前，他担任瑞思迈公司（一家服务于睡眠呼吸障碍和呼吸市场的医疗器械公司）的董事、总裁兼首席执行官。 他于2003年1月加入瑞思迈，成为美洲公司的总裁兼首席运营官，并于2004年9月晋升至瑞思迈公司的总裁。在2008年1月被任命为公司总裁、首席执行官兼董事之前，他曾担任多个职务。在加入瑞思迈之前，从1998年1月至2002年12月，他在Nanogen公司（一家DNA研究和医疗诊断公司）担任多个职务，包括总裁兼首席财务官。在1998年之前他在仪器实验室、宝洁公司和通用电气公司担任各类营销、销售和财务职位。他是Volcano公司的董事。在过往五年中， 他还担任瑞思迈的董事。
Kieran T. Gallahue,Other Current Public Company Directorships:Envista Holdings Corporation, since 2019;Chair of the Nominating and Governance Committee, since 2019.Other Public Company Directorships Previously Held:Arena Pharmaceuticals, Inc., from 2018 to 2022;Member of the Audit Committee, from 2018 to 2022;Intersect ENT, Inc., from 2015 to 2022;Chairman of the Board, from 2020 to 2022;Member of the Audit Committee, from 2015 to 2022;CareFusion Corporation, from 2011 to 2015;Volcano Corporation, from 2007 to 2015;ResMed, Inc., from 2008 to 2011.Select Professional Experience and Highlights:CareFusion Corporation, a global medical technology company (acquired by Becton, Dickinson and Company in March 2015);Chairman and Chief Executive Officer, from 2011 until his retirement in 2015;ResMed, Inc. Chief Executive Officer, from 2008 to 2011;President, from 2004 to 2011;President and Chief Operating Officer, Americas, from 2003 to 2004.Nanogen, Inc. Various positions, including President and Chief Financial Officer, from 1998 to 2002;Prior to 1998, various marketing, sales, and financial positions within Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company.Served on the Board and Executive Committee, and as Chairman of the International Committee and Treasurer of Advanced Medical Technology Association (AdvaMed).- Kieran T. Gallahue是公司董事会主席及行政总裁。在2011年1月加入公司之前，他担任瑞思迈公司（一家服务于睡眠呼吸障碍和呼吸市场的医疗器械公司）的董事、总裁兼首席执行官。 他于2003年1月加入瑞思迈，成为美洲公司的总裁兼首席运营官，并于2004年9月晋升至瑞思迈公司的总裁。在2008年1月被任命为公司总裁、首席执行官兼董事之前，他曾担任多个职务。在加入瑞思迈之前，从1998年1月至2002年12月，他在Nanogen公司（一家DNA研究和医疗诊断公司）担任多个职务，包括总裁兼首席财务官。在1998年之前他在仪器实验室、宝洁公司和通用电气公司担任各类营销、销售和财务职位。他是Volcano公司的董事。在过往五年中， 他还担任瑞思迈的董事。
- Kieran T. Gallahue,Other Current Public Company Directorships:Envista Holdings Corporation, since 2019;Chair of the Nominating and Governance Committee, since 2019.Other Public Company Directorships Previously Held:Arena Pharmaceuticals, Inc., from 2018 to 2022;Member of the Audit Committee, from 2018 to 2022;Intersect ENT, Inc., from 2015 to 2022;Chairman of the Board, from 2020 to 2022;Member of the Audit Committee, from 2015 to 2022;CareFusion Corporation, from 2011 to 2015;Volcano Corporation, from 2007 to 2015;ResMed, Inc., from 2008 to 2011.Select Professional Experience and Highlights:CareFusion Corporation, a global medical technology company (acquired by Becton, Dickinson and Company in March 2015);Chairman and Chief Executive Officer, from 2011 until his retirement in 2015;ResMed, Inc. Chief Executive Officer, from 2008 to 2011;President, from 2004 to 2011;President and Chief Operating Officer, Americas, from 2003 to 2004.Nanogen, Inc. Various positions, including President and Chief Financial Officer, from 1998 to 2002;Prior to 1998, various marketing, sales, and financial positions within Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company.Served on the Board and Executive Committee, and as Chairman of the International Committee and Treasurer of Advanced Medical Technology Association (AdvaMed).
- James F. Hinrichs
James F. Hinrichs 于 2014 年 4 月被任命为董事会成员。自 2015 年 4 月起，他担任上市诊断公司 Alere Inc 的执行副总裁兼首席财务官。从 2010 年 12 月到 2015 年 3 月，他担任上市医疗技术公司 CareFusion Corporation 的首席财务官，然后将其出售给 Becton Dickinson。他曾于 2010 年 1 月至 2010 年 12 月担任 CareFusion 的全球客户支持高级副总裁，并于 2009 年 1 月至 2010 年 1 月担任其财务总监高级副总裁。在加入 CareFusion 之前，该公司从 Cardinal Health, Inc. 分拆出来。 ，自 2004 年以来，他在 Cardinal Health 担任多个职位，包括 Cardinal Health 的执行副总裁和公司财务总监，以及其医疗保健供应链服务部门的执行副总裁兼首席财务官。在 Merck & Co 担任了十多年的财务和营销职务后，他加入了 Cardinal Health。他拥有卡内基梅隆大学的商业本科和研究生学位。
James F. Hinrichs was appointed to the Board in April 2014. Since April 2015 he has served as Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company. From December 2010 through March 2015 he served as Chief Financial Officer of CareFusion Corporation, a publicly traded medical technology company, prior to its sale to Becton Dickinson. He previously served as CareFusion's Senior Vice President, Global Customer Support, from January 2010 to December 2010 and as its Senior Vice President, Controller, from January 2009 to January 2010. Prior to joining CareFusion when it was spun off from Cardinal Health, Inc., he worked since 2004 at Cardinal Health in various positions including Executive Vice President and Corporate Controller of Cardinal Health, and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following over a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.- James F. Hinrichs 于 2014 年 4 月被任命为董事会成员。自 2015 年 4 月起，他担任上市诊断公司 Alere Inc 的执行副总裁兼首席财务官。从 2010 年 12 月到 2015 年 3 月，他担任上市医疗技术公司 CareFusion Corporation 的首席财务官，然后将其出售给 Becton Dickinson。他曾于 2010 年 1 月至 2010 年 12 月担任 CareFusion 的全球客户支持高级副总裁，并于 2009 年 1 月至 2010 年 1 月担任其财务总监高级副总裁。在加入 CareFusion 之前，该公司从 Cardinal Health, Inc. 分拆出来。 ，自 2004 年以来，他在 Cardinal Health 担任多个职位，包括 Cardinal Health 的执行副总裁和公司财务总监，以及其医疗保健供应链服务部门的执行副总裁兼首席财务官。在 Merck & Co 担任了十多年的财务和营销职务后，他加入了 Cardinal Health。他拥有卡内基梅隆大学的商业本科和研究生学位。
- James F. Hinrichs was appointed to the Board in April 2014. Since April 2015 he has served as Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company. From December 2010 through March 2015 he served as Chief Financial Officer of CareFusion Corporation, a publicly traded medical technology company, prior to its sale to Becton Dickinson. He previously served as CareFusion's Senior Vice President, Global Customer Support, from January 2010 to December 2010 and as its Senior Vice President, Controller, from January 2009 to January 2010. Prior to joining CareFusion when it was spun off from Cardinal Health, Inc., he worked since 2004 at Cardinal Health in various positions including Executive Vice President and Corporate Controller of Cardinal Health, and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following over a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.
- Thomas J. Leonard
Thomas J. Leonard是Medical System的总裁。2011年8月之前，他一直担任Dispensing Technologies的总裁。在离职前，自2008年6月起担任Cardinal Health负责临床服务的高级副总裁兼总经理。2005年6月至2008年6月，他是Mckesson公司（医疗保健服务公司）负责门诊解决方案的高级副总裁兼总经理。从2000年7月至2005年6月，他是Picis公司（急性护理产品及服务的供应商）的执行副总裁。
Thomas J. Leonard joined Agiliti, Inc. as Chief Executive Officer and has been a member of Agiliti, Inc. Board of Directors since April 2015. Prior to joining Agiliti, Inc., Mr. Leonard served as the President of Medical Systems for CareFusion Corporation, where he led the $2.4 billion revenue global medical device segment, which includes Alaris infusion pumps, Pyxis automated dispensing and patient identification systems, and AVEA and LTV series ventilators and respiratory diagnostics products. Prior to joining CareFusion in 2008 Mr. Leonard served as the Senior Vice President and General Manager of Ambulatory Solutions for McKesson Provider Technologies, and prior to that, Executive Vice President of Operations for Picis, Inc. Mr. Leonard has a bachelor's degree in Engineering from the United States Naval Academy and an MBA from S.C Johnson Graduate School of Management at Cornell University. Mr. Leonard is an experienced senior executive with extensive operating experience leading businesses focused on medical devices, services and healthcare IT.- Thomas J. Leonard是Medical System的总裁。2011年8月之前，他一直担任Dispensing Technologies的总裁。在离职前，自2008年6月起担任Cardinal Health负责临床服务的高级副总裁兼总经理。2005年6月至2008年6月，他是Mckesson公司（医疗保健服务公司）负责门诊解决方案的高级副总裁兼总经理。从2000年7月至2005年6月，他是Picis公司（急性护理产品及服务的供应商）的执行副总裁。
- Thomas J. Leonard joined Agiliti, Inc. as Chief Executive Officer and has been a member of Agiliti, Inc. Board of Directors since April 2015. Prior to joining Agiliti, Inc., Mr. Leonard served as the President of Medical Systems for CareFusion Corporation, where he led the $2.4 billion revenue global medical device segment, which includes Alaris infusion pumps, Pyxis automated dispensing and patient identification systems, and AVEA and LTV series ventilators and respiratory diagnostics products. Prior to joining CareFusion in 2008 Mr. Leonard served as the Senior Vice President and General Manager of Ambulatory Solutions for McKesson Provider Technologies, and prior to that, Executive Vice President of Operations for Picis, Inc. Mr. Leonard has a bachelor's degree in Engineering from the United States Naval Academy and an MBA from S.C Johnson Graduate School of Management at Cornell University. Mr. Leonard is an experienced senior executive with extensive operating experience leading businesses focused on medical devices, services and healthcare IT.
- Joan Stafslien
Joan Stafslien是公司的执行副总裁，总法律顾问，首席合规官和秘书。 她曾任公司执行副总裁、总法律顾问兼秘书，2010年6月起额外担任首席合规官。之前，自2008年7月以来，她曾担任Cardinal Health负责临床和的医疗产品的高级副总裁兼总法律顾问。从2004年8月至2008年7月，她担任负责临床技术和基本健康服务的高级副总裁兼总法律顾问。从1999年3月至2004年7月在Cardinal Health收购Alaris时，她担任ALARIS医疗系统公司的副总法律顾问和助理总法律顾问时。从1998年5月至1999年2月，她曾担任Alaris的高级企业法律顾问。在加入Alaris前，她是Brobeck，Phleger& Harrison律师事务所和Luce,Forward,Hamilton&Scripps律师事务所的合伙人。
Joan Stafslien has served as a director of Ra Medical since April 2020. Prior to that, she served as Executive Vice President, General Counsel and Corporate Secretary of Nuvasive, Inc. from October 2016 through June 2018 and then as an Executive Consultant from June 2018 through October 2019. Previously, Ms. Stafslien served as General Counsel, Corporate Secretary and Chief Compliance Officer of CareFusion Corporation, where she led the legal team through the spin-off from Cardinal Health, Inc. in 2009 until its acquisition by Becton, Dickinson and Company in March 2015. Prior to that, Ms. Stafslien was the segment general counsel of Cardinal Health’s Clinical Technologies and Services from 2004 to 2009 joining Cardinal Health through the acquisition of Alaris Medical Systems in 2004 where she served as deputy general counsel and assistant secretary. Prior to joining Alaris, she was in private practice with Brobeck, Phleger & Harrison.- Joan Stafslien是公司的执行副总裁，总法律顾问，首席合规官和秘书。 她曾任公司执行副总裁、总法律顾问兼秘书，2010年6月起额外担任首席合规官。之前，自2008年7月以来，她曾担任Cardinal Health负责临床和的医疗产品的高级副总裁兼总法律顾问。从2004年8月至2008年7月，她担任负责临床技术和基本健康服务的高级副总裁兼总法律顾问。从1999年3月至2004年7月在Cardinal Health收购Alaris时，她担任ALARIS医疗系统公司的副总法律顾问和助理总法律顾问时。从1998年5月至1999年2月，她曾担任Alaris的高级企业法律顾问。在加入Alaris前，她是Brobeck，Phleger& Harrison律师事务所和Luce,Forward,Hamilton&Scripps律师事务所的合伙人。
- Joan Stafslien has served as a director of Ra Medical since April 2020. Prior to that, she served as Executive Vice President, General Counsel and Corporate Secretary of Nuvasive, Inc. from October 2016 through June 2018 and then as an Executive Consultant from June 2018 through October 2019. Previously, Ms. Stafslien served as General Counsel, Corporate Secretary and Chief Compliance Officer of CareFusion Corporation, where she led the legal team through the spin-off from Cardinal Health, Inc. in 2009 until its acquisition by Becton, Dickinson and Company in March 2015. Prior to that, Ms. Stafslien was the segment general counsel of Cardinal Health’s Clinical Technologies and Services from 2004 to 2009 joining Cardinal Health through the acquisition of Alaris Medical Systems in 2004 where she served as deputy general counsel and assistant secretary. Prior to joining Alaris, she was in private practice with Brobeck, Phleger & Harrison.
- Gordon LaFortune
Gordon LaFortune是负责EMEA/APAC商业运营和全球输液耗材的执行副总裁。从2011年8月至2012年7月，他担任公司负责国际商业运营的执行副总裁。2011年8月之前，他是公司负责输液业务的高级副总裁兼总经理。在此之前，从2004年11月至2008年12月，他担任Cardinal Health负责感染预防业务的总裁。从2001年6月至2004年11月，他是Cardinal Health负责国际业务的总裁。从1999年2月至2001年6月，他是加拿大卫生部的副总裁兼总经理。在加入Cardinal Health之前， 他是加拿大医疗保健公司（Cardinal Health于1999年2月收购该公司）的副总裁兼总经理。在1996年从该公司离职前，他还在Allegiance and Baxter International（医疗保健产品和服务的制造商和营销商）担任各类营销、销售和运营职位。
Gordon LaFortune,Mr. LaFortune has been Carefusion Corporation Executive Vice President, EMEA/ANZ Commercial Operations and Global Infusion Disposables since August 2013. From July 2012 to August 2013 he served as Carefusion Corporation Executive Vice President, EMEA/APAC Commercial Operations and Global Infusion Disposables. From August 2011 to July 2012 Mr. LaFortune served as Carefusion Corporation Executive Vice President, International Commercial Operations. From August 2009 to August 2011 Mr. LaFortune was Carefusion Corporation Senior Vice President and General Manager, Infusion. Prior to Carefusion Corporation spinoff from Cardinal Health in August 2009 Mr. LaFortune served as President of the Infection Prevention business of Cardinal Health, from November 2004 to December 2008. From June 2001 to November 2004 Mr. LaFortune was President, International for Cardinal Health, and from February 1999 to June 2001 Mr. LaFortune was Vice President and General Manager for Cardinal Health Canada. Before joining Cardinal Health, Mr. LaFortune was Vice President and General Manager for Allegiance Healthcare Canada, which was acquired by Cardinal Health in February 1999. Mr. LaFortune also held various marketing, sales and operations positions at Allegiance and Baxter International, a manufacturer and marketer of healthcare products and services, prior to Baxter's spinoff of the Allegiance business in 1996.- Gordon LaFortune是负责EMEA/APAC商业运营和全球输液耗材的执行副总裁。从2011年8月至2012年7月，他担任公司负责国际商业运营的执行副总裁。2011年8月之前，他是公司负责输液业务的高级副总裁兼总经理。在此之前，从2004年11月至2008年12月，他担任Cardinal Health负责感染预防业务的总裁。从2001年6月至2004年11月，他是Cardinal Health负责国际业务的总裁。从1999年2月至2001年6月，他是加拿大卫生部的副总裁兼总经理。在加入Cardinal Health之前， 他是加拿大医疗保健公司（Cardinal Health于1999年2月收购该公司）的副总裁兼总经理。在1996年从该公司离职前，他还在Allegiance and Baxter International（医疗保健产品和服务的制造商和营销商）担任各类营销、销售和运营职位。
- Gordon LaFortune,Mr. LaFortune has been Carefusion Corporation Executive Vice President, EMEA/ANZ Commercial Operations and Global Infusion Disposables since August 2013. From July 2012 to August 2013 he served as Carefusion Corporation Executive Vice President, EMEA/APAC Commercial Operations and Global Infusion Disposables. From August 2011 to July 2012 Mr. LaFortune served as Carefusion Corporation Executive Vice President, International Commercial Operations. From August 2009 to August 2011 Mr. LaFortune was Carefusion Corporation Senior Vice President and General Manager, Infusion. Prior to Carefusion Corporation spinoff from Cardinal Health in August 2009 Mr. LaFortune served as President of the Infection Prevention business of Cardinal Health, from November 2004 to December 2008. From June 2001 to November 2004 Mr. LaFortune was President, International for Cardinal Health, and from February 1999 to June 2001 Mr. LaFortune was Vice President and General Manager for Cardinal Health Canada. Before joining Cardinal Health, Mr. LaFortune was Vice President and General Manager for Allegiance Healthcare Canada, which was acquired by Cardinal Health in February 1999. Mr. LaFortune also held various marketing, sales and operations positions at Allegiance and Baxter International, a manufacturer and marketer of healthcare products and services, prior to Baxter's spinoff of the Allegiance business in 1996.
- Donald Abbey
Donald Abbey是负责质量监管和医疗事务的执行副总裁。2011年11月起，他担任负责质量及监管事务的高级副总裁。在此之前，自2007年3月起，他曾担任Cardinal Health负责质量和基本健康的法规事务、临床和医疗产品的高级副总裁。在加入Cardinal Health之前，从2006年2月至2007年3月，他担任Respironics公司（一家服务于全球睡眠和呼吸市场的医疗器械公司）负责重症监护部门的法规事务和质量保证的副总裁。此前，他曾在医疗保健行业担任多个领导职务，包括Welch Allyn公司心肺业务部的总经理；Protocol Systems公司负责质量保证和法规事务的副总裁；和Heartstream公司负责质量的董事。
Donald Abbey,Mr. Abbey has served as Carefusion Corporation Executive Vice President, Quality, Regulatory and Medical Affairs since November 2011. From August 2009 to November 2011 Mr. Abbey served as Carefusion Corporation Senior Vice President, Quality and Regulatory Affairs. Prior to Carefusion Corporation spinoff from Cardinal Health in August 2009 Mr. Abbey served as Senior Vice President, Quality and Regulatory Affairs - Clinical and Medical Products of Cardinal Health, since March 2007. Prior to joining Cardinal Health, from February 2006 to March 2007 Mr. Abbey served as Vice President, Regulatory Affairs and Quality Assurance for the Critical Care division of Respironics, Inc., a medical device firm serving the global sleep and respiratory markets. Previously, he held a number of leadership roles within the healthcare industry, including general manager of Welch Allyn's cardiopulmonary business; vice president of Quality Assurance and Regulatory Affairs for Protocol Systems, Inc.; and director of Quality Assurance for Heartstream, Inc.- Donald Abbey是负责质量监管和医疗事务的执行副总裁。2011年11月起，他担任负责质量及监管事务的高级副总裁。在此之前，自2007年3月起，他曾担任Cardinal Health负责质量和基本健康的法规事务、临床和医疗产品的高级副总裁。在加入Cardinal Health之前，从2006年2月至2007年3月，他担任Respironics公司（一家服务于全球睡眠和呼吸市场的医疗器械公司）负责重症监护部门的法规事务和质量保证的副总裁。此前，他曾在医疗保健行业担任多个领导职务，包括Welch Allyn公司心肺业务部的总经理；Protocol Systems公司负责质量保证和法规事务的副总裁；和Heartstream公司负责质量的董事。
- Donald Abbey,Mr. Abbey has served as Carefusion Corporation Executive Vice President, Quality, Regulatory and Medical Affairs since November 2011. From August 2009 to November 2011 Mr. Abbey served as Carefusion Corporation Senior Vice President, Quality and Regulatory Affairs. Prior to Carefusion Corporation spinoff from Cardinal Health in August 2009 Mr. Abbey served as Senior Vice President, Quality and Regulatory Affairs - Clinical and Medical Products of Cardinal Health, since March 2007. Prior to joining Cardinal Health, from February 2006 to March 2007 Mr. Abbey served as Vice President, Regulatory Affairs and Quality Assurance for the Critical Care division of Respironics, Inc., a medical device firm serving the global sleep and respiratory markets. Previously, he held a number of leadership roles within the healthcare industry, including general manager of Welch Allyn's cardiopulmonary business; vice president of Quality Assurance and Regulatory Affairs for Protocol Systems, Inc.; and director of Quality Assurance for Heartstream, Inc.